Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Bought by Swiss National Bank

Swiss National Bank raised its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) by 1.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 110,000 shares of the company’s stock after purchasing an additional 2,000 shares during the quarter. Swiss National Bank owned about 0.19% of Zentalis Pharmaceuticals worth $2,215,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Arizona State Retirement System boosted its holdings in shares of Zentalis Pharmaceuticals by 3.9% in the fourth quarter. Arizona State Retirement System now owns 12,863 shares of the company’s stock valued at $259,000 after acquiring an additional 480 shares in the last quarter. Metropolitan Life Insurance Co NY boosted its holdings in shares of Zentalis Pharmaceuticals by 24.1% in the third quarter. Metropolitan Life Insurance Co NY now owns 2,828 shares of the company’s stock valued at $61,000 after acquiring an additional 550 shares in the last quarter. Captrust Financial Advisors boosted its holdings in shares of Zentalis Pharmaceuticals by 15,160.0% in the first quarter. Captrust Financial Advisors now owns 763 shares of the company’s stock valued at $35,000 after acquiring an additional 758 shares in the last quarter. ProShare Advisors LLC boosted its holdings in shares of Zentalis Pharmaceuticals by 7.9% in the fourth quarter. ProShare Advisors LLC now owns 10,759 shares of the company’s stock valued at $217,000 after acquiring an additional 791 shares in the last quarter. Finally, AXA S.A. boosted its holdings in shares of Zentalis Pharmaceuticals by 0.4% in the third quarter. AXA S.A. now owns 228,827 shares of the company’s stock valued at $4,956,000 after acquiring an additional 985 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of analysts recently commented on ZNTL shares. Jefferies Financial Group decreased their price objective on shares of Zentalis Pharmaceuticals from $120.00 to $70.00 in a report on Friday, May 19th. Stifel Nicolaus lowered their target price on shares of Zentalis Pharmaceuticals from $46.00 to $45.00 in a research report on Thursday, May 11th. Finally, HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of Zentalis Pharmaceuticals in a research report on Thursday, March 2nd. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Zentalis Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $46.00.

Zentalis Pharmaceuticals Price Performance

ZNTL stock opened at $27.16 on Friday. The company’s 50 day simple moving average is $21.12 and its 200-day simple moving average is $20.81. The firm has a market capitalization of $1.62 billion, a PE ratio of -6.33 and a beta of 1.84. Zentalis Pharmaceuticals, Inc. has a 12 month low of $15.55 and a 12 month high of $32.34.

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) last released its quarterly earnings results on Wednesday, May 10th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.11). As a group, sell-side analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -4.32 earnings per share for the current year.

Zentalis Pharmaceuticals Company Profile

(Get Rating)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.